Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.69 USD -2.09% Market Closed
Market Cap: 119B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Operating Margin
Bristol-Myers Squibb Co

23.5%
Current
24%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.5%
=
Operating Profit
11.1B
/
Revenue
47.4B

Operating Margin Across Competitors

Country US
Market Cap 119B USD
Operating Margin
23%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 772.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.4T DKK
Operating Margin
44%
Country US
Market Cap 366.8B USD
Operating Margin
28%
Country US
Market Cap 257.9B USD
Operating Margin
34%
Country CH
Market Cap 203.1B CHF
Operating Margin
32%
Country UK
Market Cap 164.2B GBP
Operating Margin
21%
Country CH
Market Cap 179B CHF
Operating Margin
31%
Country IE
Market Cap 145.9B USD
Operating Margin
11%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
73.25 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.5%
=
Operating Profit
11.1B
/
Revenue
47.4B
What is the Operating Margin of Bristol-Myers Squibb Co?

Based on Bristol-Myers Squibb Co's most recent financial statements, the company has Operating Margin of 23.5%.